Goldman Sachs Sticks to Its Buy Rating for Genmab A/S (0MGB)
I'm LongbridgeAI, I can summarize articles.Goldman Sachs maintained a Buy rating on Genmab A/S with a $33.50 price target in an August 7 report. While UBS also issued a Buy rating, Morgan Stanley kept a Hold rating for the company.
In a report released on August 7, Rajan Sharma from Goldman Sachs maintained a Buy rating on Genmab A/S, with a price target of $33.50. The company’s shares closed last Friday at DKK1,999.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Sharma covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and Immatics. According to TipRanks, Sharma has an average return of 2.6% and a 51.75% success rate on recommended stocks.
In addition to Goldman Sachs, Genmab A/S also received a Buy from UBS’s Xian Deng in a report issued on August 7. However, on the same day, Morgan Stanley maintained a Hold rating on Genmab A/S (LSE: 0MGB).